[Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
Nagahara
Akihito
A
Department of Gastroenterology, Juntendo University School of Medicine.
Sato
Nobuhiro
N
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000008:administration & dosage / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017291:Clarithromycin / Q000008:administration & dosage / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D064747:Lansoprazole; D008795:Metronidazole / Q000008:administration & dosage / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives; D010349:Patient Compliance; D054328:Proton Pump Inhibitors; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D008795:Metronidazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole